TW200528104A - Combination therapy for hcv infection - Google Patents
Combination therapy for hcv infection Download PDFInfo
- Publication number
- TW200528104A TW200528104A TW093130756A TW93130756A TW200528104A TW 200528104 A TW200528104 A TW 200528104A TW 093130756 A TW093130756 A TW 093130756A TW 93130756 A TW93130756 A TW 93130756A TW 200528104 A TW200528104 A TW 200528104A
- Authority
- TW
- Taiwan
- Prior art keywords
- day
- therapeutic combination
- dose
- sufficient
- interferon
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 21
- 238000002648 combination therapy Methods 0.000 title description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 75
- 108010050904 Interferons Proteins 0.000 claims abstract description 53
- 102000014150 Interferons Human genes 0.000 claims abstract description 53
- 229940079322 interferon Drugs 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 73
- 238000011282 treatment Methods 0.000 claims description 45
- 238000009472 formulation Methods 0.000 claims description 21
- 108010047761 Interferon-alpha Proteins 0.000 claims description 11
- 102000006992 Interferon-alpha Human genes 0.000 claims description 11
- 229940002988 pegasys Drugs 0.000 claims description 5
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 5
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims description 5
- 229940106366 pegintron Drugs 0.000 claims description 5
- 229940090438 infergen Drugs 0.000 claims description 3
- 108010006088 interferon alfa-n1 Proteins 0.000 claims description 3
- 108010010648 interferon alfacon-1 Proteins 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 108010055511 interferon alfa-2c Proteins 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 238000011284 combination treatment Methods 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract description 3
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 208000006154 Chronic hepatitis C Diseases 0.000 description 4
- 208000010710 hepatitis C virus infection Diseases 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229940055354 copegus Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000116710 Ferula foetidissima Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241001520299 Phascolarctos cinereus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51073303P | 2003-10-11 | 2003-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200528104A true TW200528104A (en) | 2005-09-01 |
Family
ID=34465143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093130756A TW200528104A (en) | 2003-10-11 | 2004-10-11 | Combination therapy for hcv infection |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050112093A1 (enExample) |
| EP (1) | EP1670462A1 (enExample) |
| JP (1) | JP2007508326A (enExample) |
| KR (1) | KR20060120037A (enExample) |
| CN (1) | CN1882335A (enExample) |
| AR (1) | AR045870A1 (enExample) |
| AU (1) | AU2004281747A1 (enExample) |
| BR (1) | BRPI0415249A (enExample) |
| CA (1) | CA2541857A1 (enExample) |
| IL (1) | IL174864A0 (enExample) |
| MX (1) | MXPA06004077A (enExample) |
| NO (1) | NO20062104L (enExample) |
| PE (1) | PE20050477A1 (enExample) |
| RU (1) | RU2006115916A (enExample) |
| TW (1) | TW200528104A (enExample) |
| WO (1) | WO2005037274A1 (enExample) |
| ZA (1) | ZA200602912B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
| US20120201883A1 (en) * | 2004-05-21 | 2012-08-09 | Accu-Break Technologies, Inc | Antiviral compositons |
| MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| US20070105781A1 (en) * | 2005-08-02 | 2007-05-10 | Steve Lyons | Inhibitors of serine proteases |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| EP2194039A1 (en) | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Process for preparing optically enriched compounds |
| CN101903392A (zh) * | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
| FR2928146B1 (fr) * | 2008-02-28 | 2010-02-19 | Saint Gobain Isover | Produit a base de fibres minerales et son procede d'obtention. |
| WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| EP2396028A2 (en) * | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| JPWO2011001897A1 (ja) * | 2009-06-30 | 2012-12-13 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 難治性のｃ型慢性肝炎の治療のための薬剤及び方法 |
| EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2017223178A1 (en) * | 2016-06-21 | 2017-12-28 | Trek Therapeutics, Pbc | Treating viral infections with impdh inhibitors |
| KR101991365B1 (ko) * | 2017-03-14 | 2019-06-21 | 국립암센터 | C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도 |
| CN109745315B (zh) * | 2019-03-08 | 2021-04-16 | 中国农业科学院兰州兽医研究所 | 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126674A (en) * | 1996-04-23 | 2005-08-31 | Vertex Pharma | Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives |
| BR9910505A (pt) * | 1998-05-15 | 2001-01-02 | Schering Corp | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c |
| US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
| US20040034206A1 (en) * | 2002-05-31 | 2004-02-19 | Schering Corporation | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors |
-
2004
- 2004-10-08 AR ARP040103677A patent/AR045870A1/es not_active Application Discontinuation
- 2004-10-11 PE PE2004000979A patent/PE20050477A1/es not_active Application Discontinuation
- 2004-10-11 TW TW093130756A patent/TW200528104A/zh unknown
- 2004-10-12 US US10/964,243 patent/US20050112093A1/en not_active Abandoned
- 2004-10-12 JP JP2006534467A patent/JP2007508326A/ja active Pending
- 2004-10-12 CN CNA2004800335847A patent/CN1882335A/zh active Pending
- 2004-10-12 MX MXPA06004077A patent/MXPA06004077A/es not_active Application Discontinuation
- 2004-10-12 EP EP04794964A patent/EP1670462A1/en not_active Withdrawn
- 2004-10-12 AU AU2004281747A patent/AU2004281747A1/en not_active Abandoned
- 2004-10-12 KR KR1020067006996A patent/KR20060120037A/ko not_active Withdrawn
- 2004-10-12 RU RU2006115916/15A patent/RU2006115916A/ru not_active Application Discontinuation
- 2004-10-12 ZA ZA200602912A patent/ZA200602912B/en unknown
- 2004-10-12 BR BRPI0415249-2A patent/BRPI0415249A/pt not_active Application Discontinuation
- 2004-10-12 WO PCT/US2004/033739 patent/WO2005037274A1/en not_active Ceased
- 2004-10-12 CA CA002541857A patent/CA2541857A1/en not_active Abandoned
-
2006
- 2006-04-09 IL IL174864A patent/IL174864A0/en unknown
- 2006-05-10 NO NO20062104A patent/NO20062104L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0415249A (pt) | 2006-12-12 |
| AU2004281747A1 (en) | 2005-04-28 |
| ZA200602912B (en) | 2007-06-27 |
| WO2005037274A1 (en) | 2005-04-28 |
| PE20050477A1 (es) | 2005-08-24 |
| US20050112093A1 (en) | 2005-05-26 |
| CA2541857A1 (en) | 2005-04-28 |
| NO20062104L (no) | 2006-05-10 |
| EP1670462A1 (en) | 2006-06-21 |
| KR20060120037A (ko) | 2006-11-24 |
| CN1882335A (zh) | 2006-12-20 |
| IL174864A0 (en) | 2008-04-13 |
| JP2007508326A (ja) | 2007-04-05 |
| RU2006115916A (ru) | 2007-12-10 |
| AR045870A1 (es) | 2005-11-16 |
| MXPA06004077A (es) | 2006-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200528104A (en) | Combination therapy for hcv infection | |
| US20020127203A1 (en) | Ribavirin-pegylated interferon alfa HCV combination therapy | |
| US20110270212A1 (en) | Pharmacokinetic control for optimized interferon delivery | |
| EP1536839B1 (en) | Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus | |
| Hadziyannis et al. | Peginterferon-α2a (40 kDa) for chronic hepatitis C | |
| JP2007501806A (ja) | ウィルス感染を治療する方法 | |
| JP2003525907A (ja) | Ｈｉｖ免疫アジュバント治療 | |
| AU2004242454B2 (en) | Renal cell carcinoma treatment | |
| US6605273B2 (en) | Renal cell carcinoma treatment | |
| JP2001288110A6 (ja) | 腎細胞ガン処置 | |
| Zhang | Pegylated interferons in the treatment of chronic hepatitis C | |
| JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
| WO2008021536A2 (en) | Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects | |
| HK1098359A (en) | Combination therapy for hcv infection | |
| Dunn et al. | Agents in Development for the Treatment of Hepatitis C | |
| HK1032533B (en) | Renal cell carcinoma treatment | |
| HK1075417B (en) | Renal cell carcinoma treatment | |
| CN103732242A (zh) | 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎 |